Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies
作者:
Claudia Gedlicka,
Birgit Schüll,
Michael Formanek,
Johannes Kornfehl,
Martin Burian,
Birgit Knerer,
Edgar Selzer,
Werner Scheithauer,
Gabriela Kornek,
期刊:
Anti-Cancer Drugs
(OVID Available online 2002)
卷期:
Volume 13,
issue 5
页码: 491-495
ISSN:0959-4973
年代: 2002
出版商: OVID
关键词: Cisplatin;mitoxantrone;palliative chemotherapy;salivary gland carcinoma
数据来源: OVID
摘要:
A phase II study was performed to assess the safety and efficacy of mitoxantrone and cisplatin in locally recurrent and/or metastatic carcinomas of the salivary glands. Between May 1997 and March 2001, a total of 14 patients were entered on this trial. All of them had previously undergone radical resection and 10 were subsequently treated with adjuvant radiation therapy with (n=3) or without (n=7) concomitant chemotherapy. Therapy according to the study protocol consisted of mitoxantrone given as i.v. bolus on day 1 at a dose of 12 mg/m2and cisplatin given as 90-min infusion at a dose of 30 mg/m2on days 1–3. We observed two partial responses (14.3%) and stabilization of disease in nine patients (64.3%); progression during therapy was noted in only three cases (21.4%). The median time to progression was 15 months (range 2–36) and the median survival time was 27 months (range 4–54). Myelosuppression was commonly observed. Leukocytopenia occurred in all patients, and was grade 3 or 4 in three (21%) and four (29%) patients. WHO grade 3 thrombocytopenia and anemia was seen in three (21%) and four (29%) patients, respectively. Non-hematologic toxicity was in general mild to moderate except for two cases (14%) of grade 3 nausea and vomiting; overall incidence rates were nausea and vomiting (n=14), stomatitis (n=6), diarrhea (n=3), alopecia (n=11), infection (n=7), increase of serum creatinine (n=3), and peripheral neuropathy (n=3). The combination of mitoxantrone and cisplatin seems to be an active and fairly well-tolerated regimen for the treatment of advanced salivary gland cancers. According to the observed high rate of abrogating progressive disease for a long duration, and the resulting promising progression-free and overall survival time, further investigation seems warranted.
点击下载:
PDF
(84KB)
返 回